Toralizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Toralizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD40 ligand
Clinical data
Legal status ?
Identifiers
CAS number 252662-47-8 N
ATC code None
KEGG D06193 YesY
Chemical data
Formula ?
Mol. mass 148,426 Daltons
 N (what is this?)  (verify)

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]

The drug was developed by IDEC Pharmaceuticals Corporation.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
  2. ^ Luebke, Robert W; Robert V House, Ian Kimber (2007). Immunotoxicology and immunopharmacology. Target Organ Toxicology Series (3 ed.). Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 131. ISBN 0-8493-3790-9.